Lindskrog Sia V, Schmøkel Sofie S, Nordentoft Iver, Lamy Philippe, Knudsen Michael, Prip Frederik, Strandgaard Trine, Jensen Jørgen Bjerggaard, Dyrskjøt Lars
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Eur Urol Open Sci. 2023 Apr 7;51:78-88. doi: 10.1016/j.euros.2023.03.006. eCollection 2023 May.
Current bulk transcriptomic classification systems for bladder cancer do not consider the level of intratumor subtype heterogeneity.
To investigate the extent and possible clinical impact of intratumor subtype heterogeneity across early and more advanced stages of bladder cancer.
We performed single-nucleus RNA sequencing (RNA-seq) of 48 bladder tumors and additional spatial transcriptomics for four of these tumors. Total bulk RNA-seq and spatial proteomics data were available from the same tumors for comparison, along with detailed clinical follow-up of the patients.
The primary outcome was progression-free survival for non-muscle-invasive bladder cancer. Cox regression analysis, log-rank tests, Wilcoxon rank-sum tests, Spearman correlation, and Pearson correlation were used for statistical analysis.
We found that the tumors exhibited varying levels of intratumor subtype heterogeneity and that the level of subtype heterogeneity can be estimated from both single-nucleus and bulk RNA-seq data, with high concordance between the two. We found that a higher class 2a weight estimated from bulk RNA-seq data is associated with worse outcome for patients with molecular high-risk class 2a tumors. The sparsity of the data generated using the DroNc-seq sequencing protocol is a limitation.
Our results indicate that discrete subtype assignments from bulk RNA-seq data may lack biological granularity and that continuous class scores may improve clinical risk stratification of patients with bladder cancer.
We found that several molecular subtypes can exist within a single bladder tumor and that continuous subtype scores can be used to identify a subgroup of patients with poor outcomes. Use of these subtype scores may improve risk stratification for patients with bladder cancer, which can help in making decisions on treatment.
当前用于膀胱癌的整体转录组分类系统未考虑肿瘤内亚型异质性的水平。
研究膀胱癌早期和更晚期阶段肿瘤内亚型异质性的程度及其可能的临床影响。
设计、设置与参与者:我们对48例膀胱肿瘤进行了单核RNA测序(RNA-seq),并对其中4例肿瘤进行了额外的空间转录组学分析。可获取同一肿瘤的总整体RNA-seq和空间蛋白质组学数据用于比较,同时还有患者的详细临床随访数据。
主要结果是非肌肉浸润性膀胱癌的无进展生存期。采用Cox回归分析、对数秩检验、Wilcoxon秩和检验、Spearman相关性分析和Pearson相关性分析进行统计分析。
我们发现肿瘤表现出不同程度的肿瘤内亚型异质性,并且亚型异质性水平可通过单核和整体RNA-seq数据进行估计,二者具有高度一致性。我们发现,从整体RNA-seq数据估计的较高的2a类权重与分子高危2a类肿瘤患者的较差预后相关。使用DroNc-seq测序方案产生的数据稀疏性是一个局限性。
我们的结果表明,来自整体RNA-seq数据的离散亚型分类可能缺乏生物学粒度,而连续类评分可能改善膀胱癌患者的临床风险分层。
我们发现单个膀胱肿瘤内可能存在几种分子亚型,并且连续亚型评分可用于识别预后较差的患者亚组。使用这些亚型评分可能改善膀胱癌患者的风险分层,这有助于做出治疗决策。